Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lapointe

Showing results (131-140 of 142) with videos related to

Pageof 15
Sort By:
The Journal of Infectious Diseases|May 11, 2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|August 3, 2023
Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in CanadaCecilia T Costiniuk, Joel Singer, Terry Lee, et al.
Nature Communications|August 19, 2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8<sup>+</sup> T-cellsEva M Stevenson, Sandra Terry, Dennis Copertino, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Canadian Surgery ForumH Atlas, N Safa, R Denis, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|June 24, 2023
Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007K M Devon, O Vergara, J C Victor, et al.
Pageof 15

Showing results (131-140 of 142) with videos related to

Sort By:
Pageof 15
The Journal of Infectious Diseases|May 11, 2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|August 3, 2023
Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in CanadaCecilia T Costiniuk, Joel Singer, Terry Lee, et al.
Nature Communications|August 19, 2022
SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8<sup>+</sup> T-cellsEva M Stevenson, Sandra Terry, Dennis Copertino, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|April 30, 2022
Canadian Surgery ForumH Atlas, N Safa, R Denis, et al.
Canadian Journal of Surgery. Journal Canadien De Chirurgie|June 24, 2023
Abstracts of presentations to the Annual Meetings of the Canadian Society of Colon and Rectal Surgeons Canadian Association of General Surgeons Canadian Association of Thoracic Surgeons: Canadian Surgery Forum, Toronto, Ont., September 6-9, 2007K M Devon, O Vergara, J C Victor, et al.
Pageof 15